Skip to content

Vitamin D action in the treatment of Depression and reduction of Cardiovascular Risk

Vitamin D Action in Depression and Cardiovascular Risk in Outpatient Treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-6yj8sj
Enrollment
Unknown
Registered
2018-08-06
Start date
2018-10-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressão

Interventions

A total of 224 adult patients in the age group of 18-59 years old, both of whom were depressed patients, were treated with antidepressants at the psychiatric outpatient clinics of two universities in
Dietary supplement
SP6.051.227

Sponsors

Universidade Federal de Pernambuco
Lead Sponsor
Hospital das Clínicas da Universidade Federal de Pernambuco
Collaborator

Eligibility

Age
18 Years to 59 Years

Inclusion criteria

Inclusion criteria: Adults in the age group of 18 to 59 years; Both sexes; People with depression; Attended in psychiatric outpatient clinics; In treatment with antidepressants

Exclusion criteria

Exclusion criteria: Exclusion Criteria: patients who are already being supplemented with vitamin D, with a personal history of psychiatric comorbidities, chronic kidney disease, hypercalcemia, neoplasias and pregnant women or breastfeeding women.

Design outcomes

Primary

MeasureTime frame
Therapeutic effects of Vitamin D on depression;   The method that will be used to verify the expected outcome will be applying the Montgomery-Asberg Depression Scale to assess the reduction in depressive symptom scores;   The presentation of the parameters used to verify if the outcome occurred will be obtained by improving the score related to the severity levels of depression after treatment with vitamin D, around 70%; ;Therapeutic action of Vitamin D on cardiovascular risk factors will be evaluated by their presence or by the evolution or alteration of the parameters evaluated.;Systemic Arterial Hypertension (SAH), through systolic blood pressure levels, diastolic blood pressure; Reduction of systolic and diastolic blood pressure levels is expected ;Lipid profile, with total cholesterol, HDL, LDL, triglycerides, total cholesterol / HDL dosages); Serum levels of total cholesterol, LDL cholesterol, triglycerides and serum HDL cholesterol levels are expected to be reduced; Coronary artery disease: coronary calcium score> 100 or> 75th percentile for age or gender, exercise test or myocardial scintigraphy showing signs of myocardial ischemia ;Stroke: clinical picture and (or) suggestive imaging;;Peripheral obstructive arterial disease: brachial ankle index <0.9; arterial stenosis detected by lower limb USG;;Atheromatosis carotidiana:      stenosis / carotid thickening;Heart Failure: Left ventricular hypertrophy or reduction of left ventricular systolic function or diastolic dysfunction, detected by the Doppler echocardiogram;;Heart Arrhythmia: detected by resting electrocardiogram, 24 hour Holter or exercise test;Diabetes Mellitus, Tolerance to Decreased Glucose or Insulin Resistance (fasting glycemia, hemoglobin A1C, TTOG, basal insulin, insulin curve, HOMA Index);Serum markers of cardiovascular risk (high sensitivity C-reactive protein, homocysteine, lipoprotein A);;Hypo- or hyperthyroidism (ultra-sensitive TSH, free T4, free T3;;Chronic Kidney Disease, assessed

Secondary

MeasureTime frame
Associations of the therapeutic effects of vitamin D with sociodemographic and clinical characteristics sociodemographic characteristics. ;The strength of possible therapeutic effects attributed to vitamin D in variables related to depression.

Countries

Brazil

Contacts

Public ContactCatarina Porto

Catarina Porto

catarinamqo@gmail.com8196557408

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Mar 1, 2026